PureTech Health plc (PRTC)

NASDAQ: PRTC · IEX Real-Time Price · USD
17.08
-1.30 (-7.07%)
At close: Dec 7, 2023, 12:57 PM
17.93
+0.85 (4.98%)
After-hours: Dec 7, 2023, 4:00 PM EST
-7.07%
Market Cap 505.61M
Revenue (ttm) 15.62M
Net Income (ttm) -50.35M
Shares Out 27.28M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 546
Open 18.12
Previous Close 18.38
Day's Range 17.08 - 18.12
52-Week Range 17.08 - 38.51
Beta 0.84
Analysts n/a
Price Target n/a
Earnings Date Aug 29, 2023

About PRTC

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ms. Daphne Zohar
Employees 111
Stock Exchange NASDAQ
Ticker Symbol PRTC
Full Company Profile

Financial Performance

In 2022, PRTC's revenue was $15.62 million, a decrease of -10.18% compared to the previous year's $17.39 million. Losses were -$50.35 million, -16.85% less than in 2021.

Financial Statements

News

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics...

Other symbols: KRTX
8 days ago - Business Wire

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

3 months ago - Business Wire

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

3 months ago - Business Wire

PureTech Announces Annual Results for Year Ended December 31, 2022

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2022.

7 months ago - Business Wire

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/...

8 months ago - Business Wire

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.

Other symbols: RPRX
9 months ago - Business Wire

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a hea...

10 months ago - Business Wire

PureTech to Present at the SVB Securities Global Biopharma Conference

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

11 months ago - Business Wire

Vedanta Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced ...

11 months ago - Business Wire

PureTech Provides End of Year Report on Key Progress

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a h...

1 year ago - Business Wire

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech's Glyph™ Platform

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech to Present at Two Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

1 year ago - Business Wire

PureTech to Present at the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastat...

1 year ago - Business Wire

PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

1 year ago - Business Wire

Form 8 (OPD) PureTech Health PLC

OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1 year ago - GlobeNewsWire

PureTech to Present at the Morgan Stanley Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Morgan Stanley Global Healthcare Conference

1 year ago - Business Wire

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-100 Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at ERS International Congress 2022

1 year ago - Business Wire

PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals

1 year ago - Business Wire

PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, In...

1 year ago - Business Wire

PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results

1 year ago - Business Wire